- Home
- ATYR vs GDEV Comparison
ATYR vs GDEV Comparison
Compare ATYR & GDEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- GDEV
- Stock Information
- Founded
- ATYR 2005
- GDEV 2009
- Country
- ATYR United States
- GDEV Cyprus
- Employees
- ATYR N/A
- GDEV N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- GDEV EDP Services
- Sector
- ATYR Health Care
- GDEV Technology
- Exchange
- ATYR Nasdaq
- GDEV Nasdaq
- Market Cap
- ATYR 327.0M
- GDEV N/A
- IPO Year
- ATYR 2015
- GDEV N/A
- Fundamental
- Price
- ATYR $3.27
- GDEV $12.41
- Analyst Decision
- ATYR Strong Buy
- GDEV Buy
- Analyst Count
- ATYR 6
- GDEV 2
- Target Price
- ATYR $18.60
- GDEV $70.00
- AVG Volume (30 Days)
- ATYR 1.7M
- GDEV 16.7K
- Earning Date
- ATYR 03-13-2025
- GDEV 04-08-2025
- Dividend Yield
- ATYR N/A
- GDEV N/A
- EPS Growth
- ATYR N/A
- GDEV N/A
- EPS
- ATYR N/A
- GDEV 2.04
- Revenue
- ATYR $235,000.00
- GDEV $432,534,000.00
- Revenue This Year
- ATYR $1,387.23
- GDEV N/A
- Revenue Next Year
- ATYR $873.22
- GDEV $9.01
- P/E Ratio
- ATYR N/A
- GDEV $6.06
- Revenue Growth
- ATYR N/A
- GDEV N/A
- 52 Week Low
- ATYR $1.42
- GDEV $12.38
- 52 Week High
- ATYR $4.66
- GDEV $42.76
- Technical
- Relative Strength Index (RSI)
- ATYR 44.59
- GDEV 32.88
- Support Level
- ATYR $3.63
- GDEV $12.50
- Resistance Level
- ATYR $3.94
- GDEV $16.00
- Average True Range (ATR)
- ATYR 0.33
- GDEV 0.83
- MACD
- ATYR -0.01
- GDEV -0.40
- Stochastic Oscillator
- ATYR 33.58
- GDEV 8.86
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.